OncoPharm podcast

Paradigm and Daraxonrasib in NSCLC

3/9/2026
0:00
14:31
Manda indietro di 15 secondi
Manda avanti di 15 secondi
PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs. Intensive Chemo if fit patients with AML. Daraxonrasib looks like a promising drug for RAS-mutant NSCLC, too. Download the Oncology Learning Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Altri episodi di "OncoPharm"